Trevi Therapeutics, Inc. (TRVI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, President & Director | 987.25k | -- | 1965 |
| Ms. Lisa Delfini | Chief Financial Officer | 604.68k | -- | 1971 |
| Dr. James V. Cassella Ph.D. | Chief Development Officer | 671.63k | -- | 1955 |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 551.43k | -- | 1953 |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | -- | -- | 1978 |
| Katie McManus | Communications Manager | -- | -- | -- |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | -- | -- | -- |
Trevi Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Corporate Governance
Upcoming Events
August 7, 2025 at 8:00 PM UTC
Trevi Therapeutics, Inc. Earnings Date